[go: up one dir, main page]

NO20062256L - Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner - Google Patents

Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner

Info

Publication number
NO20062256L
NO20062256L NO20062256A NO20062256A NO20062256L NO 20062256 L NO20062256 L NO 20062256L NO 20062256 A NO20062256 A NO 20062256A NO 20062256 A NO20062256 A NO 20062256A NO 20062256 L NO20062256 L NO 20062256L
Authority
NO
Norway
Prior art keywords
pyrimidin
hydroxyalkyl
ones
substituted pyrido
formula
Prior art date
Application number
NO20062256A
Other languages
English (en)
Inventor
David Michael Goldstein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20062256L publication Critical patent/NO20062256L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en forbindelse med formel I hvor X1, Ar1, R1 og R2 er som definert her samt preparater omfattende samme. Foreliggende oppfinnelse tilveiebringer også fremgangsmåter for anvendelse av forbindelser med formel I ved behandling av p38-medierte lidelser hos en pasient.
NO20062256A 2003-11-13 2006-05-19 Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner NO20062256L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51978903P 2003-11-13 2003-11-13
PCT/EP2004/012475 WO2005047284A1 (en) 2003-11-13 2004-11-04 Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones

Publications (1)

Publication Number Publication Date
NO20062256L true NO20062256L (no) 2006-06-06

Family

ID=34590444

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062256A NO20062256L (no) 2003-11-13 2006-05-19 Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner

Country Status (26)

Country Link
US (2) US7348331B2 (no)
EP (1) EP1685131B1 (no)
JP (1) JP4616839B2 (no)
KR (1) KR100816321B1 (no)
CN (1) CN100455582C (no)
AR (1) AR046705A1 (no)
AT (1) ATE356124T1 (no)
AU (1) AU2004289428B2 (no)
BR (1) BRPI0416030A (no)
CA (1) CA2544247A1 (no)
CO (1) CO5690600A2 (no)
DE (1) DE602004005238T2 (no)
DK (1) DK1685131T3 (no)
ES (1) ES2281843T3 (no)
HR (1) HRP20070132T3 (no)
IL (1) IL175284A0 (no)
MY (1) MY141011A (no)
NO (1) NO20062256L (no)
NZ (1) NZ546634A (no)
PL (1) PL1685131T3 (no)
PT (1) PT1685131E (no)
RU (1) RU2348632C2 (no)
SI (1) SI1685131T1 (no)
TW (1) TWI349670B (no)
WO (1) WO2005047284A1 (no)
ZA (1) ZA200603829B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049503B1 (en) 2006-07-17 2012-12-19 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
CA2672848A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Compounds and methods for amino-alkylenediol synthesis
CN101679211A (zh) * 2007-06-15 2010-03-24 霍夫曼-拉罗奇有限公司 用于制备3-氨基-戊-1,5-二醇的新方法
CA2784749C (en) * 2009-12-18 2017-12-12 E. Premkumar Reddy Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
SI3102577T1 (sl) * 2014-02-07 2019-03-29 Principia Biopharma Inc. Derivati kinolona kot zaviralci receptorja fibroblastnega rastnega faktorja
EP3334735B1 (en) 2015-08-11 2025-08-13 Principia Biopharma Inc. Processes for preparing an fgfr inhibitor
CN105418609B (zh) * 2015-12-31 2017-06-23 山东大学 4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3901162A1 (en) 2016-06-02 2021-10-27 AbbVie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
SG11201809882XA (en) 2016-06-08 2018-12-28 Support Venture Gmbh Pharmaceutical combinations for treating cancer
EP3500258A1 (en) 2016-08-17 2019-06-26 Support-Venture GmbH Method of preventing or treating hearing loss
BR112019020754A2 (pt) * 2017-04-04 2020-04-28 Strekin Ag métodos de prevenção ou tratamento de doenças oftalmológicas
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
RS63581B1 (sr) 2017-10-05 2022-10-31 Fulcrum Therapeutics Inc Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju lečenja fshd
BR112020010694A2 (pt) 2017-12-01 2020-11-10 Abbvie Inc. agonista de receptor de glicocorticoides e imunoconjugados do mesmo
MX2020012499A (es) 2018-05-21 2021-02-15 Nerviano Medical Sciences Srl Compuestos heterocondensados de piridonas y su uso como inhibidores de la idh.
WO2020011661A1 (en) 2018-07-13 2020-01-16 Kinarus Ag Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
CN115038700B (zh) 2019-11-08 2025-07-25 内尔维亚诺医疗科学公司 偕二取代的杂环化合物及其作为idh抑制剂的用途
WO2022034031A1 (en) 2020-08-11 2022-02-17 Kinarus Ag Methods of preventing or treating covid-19 and related viral diseases or disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215216A (en) 1979-04-18 1980-07-29 American Home Products Corporation 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives
US5037826A (en) 1986-10-15 1991-08-06 Schering Corporation 1-substituted naphthyridine and pyridopyrazine derivatives
AU598093B2 (en) 1987-02-07 1990-06-14 Wellcome Foundation Limited, The Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
US5149699A (en) * 1991-10-24 1992-09-22 American Home Products Corporation Substituted pyridopyrimidines useful as antgiotensin II antagonists
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
RU2191188C2 (ru) 1994-11-14 2002-10-20 Варнер-Ламберт Компани Производные 6-арилпиридо[2,3-d]-пиримидины и -нафтиридины, фармацевтическая композиция, обладающая ингибирующим действием клеточной пролиферации, вызываемой протеиновой тирозинкиназой, и способ ингибирования клеточной пролиферации
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
ATE391719T1 (de) 1997-02-05 2008-04-15 Warner Lambert Co Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation
AU763839B2 (en) 1998-05-26 2003-07-31 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US7053070B2 (en) 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
SK10772002A3 (sk) 2000-01-27 2004-01-08 Warner-Lambert Company Pyridopyrimidinónové deriváty na liečbu neurodegeneratívnych ochorení
HUP0300136A2 (en) 2000-03-06 2003-05-28 Warner Lambert Co 5-alkylpyrido [2,3-d]pyrimidines tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
WO2002018380A1 (en) * 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
US6518276B2 (en) 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
BRPI0207172B8 (pt) * 2001-02-12 2021-05-25 Hoffmann La Roche pirido-pirimidinas 6-substituída, sua composição e seu uso, bem como seu intermediário
BR122016021801B8 (pt) * 2002-01-22 2021-05-25 Warner Lambert Co compostos 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
FR2897336B1 (fr) 2006-02-10 2010-07-30 Ranger France Support d'aile pour vehicule automobile

Also Published As

Publication number Publication date
TWI349670B (en) 2011-10-01
KR100816321B1 (ko) 2008-03-24
BRPI0416030A (pt) 2007-01-02
EP1685131B1 (en) 2007-03-07
US20080119497A1 (en) 2008-05-22
HRP20070132T3 (en) 2007-05-31
JP2007510686A (ja) 2007-04-26
AR046705A1 (es) 2005-12-21
NZ546634A (en) 2010-01-29
HK1099021A1 (zh) 2007-08-03
PL1685131T3 (pl) 2007-08-31
ES2281843T3 (es) 2007-10-01
ZA200603829B (en) 2007-10-31
WO2005047284A1 (en) 2005-05-26
TW200526657A (en) 2005-08-16
CO5690600A2 (es) 2006-10-31
IL175284A0 (en) 2006-09-05
MY141011A (en) 2010-02-25
CA2544247A1 (en) 2005-05-26
EP1685131A1 (en) 2006-08-02
ATE356124T1 (de) 2007-03-15
RU2006120486A (ru) 2008-01-20
PT1685131E (pt) 2007-05-31
JP4616839B2 (ja) 2011-01-19
DE602004005238T2 (de) 2007-11-08
KR20060086417A (ko) 2006-07-31
US20050107408A1 (en) 2005-05-19
AU2004289428B2 (en) 2010-06-03
SI1685131T1 (sl) 2007-06-30
CN1882585A (zh) 2006-12-20
DE602004005238D1 (de) 2007-04-19
US7348331B2 (en) 2008-03-25
CN100455582C (zh) 2009-01-28
US7750016B2 (en) 2010-07-06
RU2348632C2 (ru) 2009-03-10
AU2004289428A1 (en) 2005-05-26
DK1685131T3 (da) 2007-07-09

Similar Documents

Publication Publication Date Title
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
NO20064000L (no) Heteroarylkoblede pyrazoloderivater
NO20063479L (no) Fosfonater, monofosfonamidater og bis-fosfonamidater for behandling av virussykdommer
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
NO20050828L (no) lndol-3-svovelderivater
NO20062335L (no) Nye diazaspiroalkaner og deres anvendelse i behandlingen av CCR8 medierte sykdommer
WO2005046603A3 (en) Pyridine compounds
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20054905L (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20061080L (no) Kondenserte pyramidinforbindelser som inhibitorer av spenningsstyrte ionekanaler
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
ATE433447T1 (de) Pyrimiidinverbindungen
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20064015L (no) Kondenserte derivater av pyrazol
NO20021358D0 (no) Alkylendiamin-substituerte heterocykler
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
NO20066055L (no) Pyridinderivater
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application